// App-Quantinova.ai

7567 : Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).

Researchers

Presenter

  • Ravi Salgia

Principal Investigators

  • R. Waide Weaver

  • Stephanie Roberson

  • Oday Hamid

  • John Polzer

  • Amy Flynt

  • Eyas Raddad

  • David R. Spigel

  • Michael R Stille

  • S. Betty Yan

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • The University of Chicago, Chicago, ILPharPoint Research Inc., Durham, NCFlorida Cancer Specialists, Fort Myers, FL

  • Eli Lilly and Company, Indianapolis, IN

  • Florida Cancer Specialists, St. Petersburg, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Circulating tumor cells

  • C-X-C motif chemokine receptor 4

Drug/Treatment

  • Carboplatin

  • Etoposide

  • Etoposide phosphate

  • LY2510924

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved